Quick Answer
OS Therapies Inc reported R&D Expense of $16.36 million for fiscal year 2025.
OS Therapies Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $16.36M | +476.3% |
| 2024 | $2.84M | -11.7% |
| 2023 | $3.22M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.76M | +210.3% | +50.2% |
| June 30, 2025 | $2.50M | +530.3% | +90.9% |
| March 31, 2025 | $1.31M | +261.8% | +8.2% |
| September 30, 2024 | $1.21M | +166.3% | +205.2% |
| June 30, 2024 | $396.6K | -60.1% | +9.6% |
| March 31, 2024 | $361.8K | -52.0% | -20.4% |
| September 30, 2023 | $454.5K | — | -54.2% |
| June 30, 2023 | $992.9K | — | +31.7% |
- OS Therapies Inc showed an increase of +476.3% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, OS Therapies Inc’s r&d expense has grown by 408.6% (from $3.22 million to $16.36 million).
- The most recent figure is from OS Therapies Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: